For instance, pharmacological inhibition of FABP4 is already being investigated for metabolic disorders [44, 45], while interventions enhancing adiponectin signaling, through PPAR-γ agonists [46] or lifestyle modifications, are known to yield metabolic improvements. This evidence concerns the gene FABP4 and metabolic disease.